<DOC>
	<DOCNO>NCT00909077</DOCNO>
	<brief_summary>In study want investigate combination therapy rituximab ( R ) + dexamethasone ( DXM ) superior monotherapy DXM patient newly diagnose idiopathic thrombocytopenic purpura ( ITP ) . Before treatment molecular study - gene expression profile - perform characterize molecular level patient respond adequately treatment compare obtain minor response . The hypothesis combination therapy superior monotherapy define . Using gene expression study up-front hypothesis method may able predict response treatment .</brief_summary>
	<brief_title>The Efficacy Dexamethasone Versus Dexamethasone Combined With Rituximab Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age 18 year Diagnosis = ITP + platelet count equal 25 Mia/l platelet count equal 50 Mia/l bleed mucous membrane . Adequate contraceptive measure within last 3 month woman childbearing potential . Performance status equal 2 Previous treatment rituximab Immunosuppressive treatment within last month except previously treat patient Other serious disease Pregnant woman nurse mother Contraindication rituximab treatment . Active infection require antibiotic treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>ITP-Rituximab-dexamethasone</keyword>
</DOC>